Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia

A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder

(2010) Francois A. Giuliano et al.   BJU INTERNATIONAL

Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?

(2009) Thierry Roumeguère et al.   BJU INTERNATIONAL

Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment

(2009) Claus G. Roehrborn et al.   BJU INTERNATIONAL

The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors

(2008) Tobias S. Köhler et al.   EUROPEAN UROLOGY

Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study

(2008) Claus G. Roehrborn et al.   JOURNAL OF UROLOGY

Effects of Phosphodiesterase Inhibitors on Tension Induced by Norepinephrine and Accumulation of Cyclic Nucleotides in Isolated Human Prostatic Tissue

(2008) Stefan Ückert et al.   UROLOGY

The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms

(2008) George T. Kedia et al.   WORLD JOURNAL OF UROLOGY